Table 2.
Systemic haemodynamic effects of single dose ABT-627 administration (Study 1).
| Predose | 30 min postdose | 8 h postdose | ||||
|---|---|---|---|---|---|---|
| ABT-627/placebo | ABT-627 | Placebo | ABT-627 | Placebo | ABT-627 | Placebo |
| 1 mg | ||||||
| MAP (mmHg) | 90 ± 3 | 89 ± 3 | 95 ± 4 | 91 ± 4 | 83 ± 3 | 85 ± 6 |
| HR (beats min−1) | 68 ± 4 | 65 ± 3 | 70 ± 4 | 66 ± 3 | 82 ± 4 | 76 ± 3 |
| CI (l min−1 m−2) | 3.1 ± 0.2 | 2.9 ± 0.3 | 3.2 ± 0.3 | 3.0 ± 0.3 | 3.7 ± 0.3 | 3.7 ± 0.5 |
| TPRI (AU) | 30 ± 2.9 | 31 ± 2.9 | 31 ± 3.5 | 31 ± 2.8 | 23 ± 2.8 | 24 ± 3.7 |
| 20 mg | ||||||
| MAP (mmHg) | 86 ± 3 | 87 ± 2 | 89 ± 2 | 91 ± 2 | 75 ± 1⋆ | 81 ± 2 |
| HR (beats min−1) | 56 ± 2 | 53 ± 2 | 59 ± 2 | 55 ± 2 | 66 ± 3 | 63 ± 3 |
| CI (l min−1 m−2) | 3.3 ± 0.3 | 3.1 ± 0.2 | 3.4 ± 0.3 | 3.1 ± 0.1 | 4.6 ± 0.4 | 4.3 ± 0.3 |
| TPRI (AU) | 29 ± 3.0 | 29 ± 1.8 | 29 ± 2.7 | 30 ± 1.9 | 18 ± 1.7 | 20 ± 2.3 |
| 40 mg | ||||||
| MAP (mmHg) | 93 ± 4 | 91 ± 3 | 96 ± 4 | 94 ± 3 | 86 ± 4 | 85 ± 4 |
| HR (beats min−1) | 58 ± 3 | 55 ± 3 | 64 ± 3 | 61 ± 3 | 74 ± 3 | 65 ± 5 |
| CI (l min−1 m−2) | 3.1 ± 0.3 | 3.1 ± 0.3 | 3.4 ± 0.3⋆ | 3.2 ± 0.3 | 4.9 ± 0.4⋆ | 4.3 ± 0.3 |
| TPRI (AU) | 32 ± 3.6 | 30 ± 2.6 | 30 ± 3.2⋆ | 30 ± 2.8 | 18 ± 1.9 | 21 ± 1.9 |
Systemic haemodynamics after single dose administration of ABT-627 or matched placebo at three dose levels: 1 (n = 6), 20 (n = 12) and 40 mg (n-6).
⋆
P < 0.05 for changes from predose, compared to placebo. Data are expressed as mean ± s.e.mean.